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Summary Sera from 182 newly diagnosed breast cancer patients were assayed for antibodies to p53 using an
enzyme-linked immunosorbent assay (ELISA) method, and antibodies were detected in 48 (26%) compared
with 1 out of 76 (1.3%) normal control volunteers (P= 0.0001). In breast cancer patients, autoantibodies were
found in all stages of disease progression: carcinoma in situ, primary invasive breast cancer and in metastatic
disease. In the subset of patients in whom sequential sera were assessed over a 6 month period, changes in the
p53 antibody titres were observed. The presence of antibodies to p53 correlated positively with high
histological grade (P = 0.0012) and a history of second primary cancer (six positive out of eight cases). The
incidence of autoantibodies was lower in those patients with a first-degree relative with breast cancer
(P = 0.046). Out of 68 patients, there was a significant correlation between positive p53 autoantibody status
and the detection of p53 protein in the tissue sections by immunocytochemistry (P = 0.002). In the
seronegative patients, positive p53 tumour staining was strongly associated with a family history of breast
cancer (P = 0.009). The p53 protein overexpressed in heritable breast cancers may therefore be less
immunogenic. The presence of p53 autoantibodies provides important additional information to
immunochemistry and may identify patients with aggressive histological types of breast cancer.
Introduction
Inactivation of the p53 gene is the commonest genetic change
in human malignancy, and may occur by mutation, complex
formation with other cellular proteins or enhanced degrada-
tion (Nigro et al., 1989; Hollstein et al., 1991; Crook et al.,
1992; Oliner et al., 1992). Mutation appears to be the com-
monest of these, occurring in between 30 and 50% of breast
cancer patients (Davidoff et al., 1991; Coles et al., 1992), and
gives rise to mutant p53 proteins of increased stability, which
can be detected by immunohistochemistry. Germ-line muta-
tions have been described in patients with the rare Li-
Fraumeni syndrome, which includes breast cancer (Malkin et
al., 1990), but recent evidence would suggest germ-line muta-
tions in p53 do not account for the majority of heritable
breast cancers (Prosser et al., 1991; Sidransky et al., 1992).
However, mechanisms of stabilisation other than mutation
may give rise to immunohistochemically detectable protein in
breast cancer families (Barnes et al., 1992). Data from large
clinical series of both early and metastatic breast cancer have
shown a correlation between p53 protein expression and
clinical outcome (Thor et al., 1992; Allred et al., 1993).
The occurrence of high levels of cellular mutant p53 often
follows critical events in malignancies. For instance,
haematopoietic cells of leukaemic patients in remission or in
chronic phase have immunohistochemically undetectable p53
levels but exhibit high p53 levels upon relapse or when
tumour cells enter blast crisis (Nakai et al., 1992). Similarly,
in cervical cancer, while p53 mutation may not be present in
the majority of tumours in early disease, mutations have been
described in lymph node metastases of human papilloma-
virus (HPV)-positive tumours. In breast cancer high nuclear
levels of p53 are often associated with advanced disease, and
correlate with known indicators of poor prognosis, such as
tumour differentiation and low progesterone receptor concen-
trations (Cattoretti et al., 1988). There is also variation in the
distribution of p53 protein expression at different phases of
the cell cycle, with accumulation at the G,-S interface
(Shaulsky et al., 1990).
Autoantibodies to p53 have been detected in the serum of
breast cancer patients (Crawford et al., 1982; Davidoff et al.,
1992; Schlichtholz et al., 1992) as well as in the serum of
patients with lung and other tumour types (Caron de Fro-
mentel et al., 1987; Winter et al., 1992). The current study
was initiated to assess the clinical implications of serum
antibodies to p53 by relating their incidence as determined by
a novel ELISA technique to both tissue p53 protein expres-
sion in the corresponding biopsy and established
clinicopathological variables in this disease.
Patients and controls
All patients presenting for treatment of newly diagnosed
breast cancer to the Breast Clinic at the Royal Liverpool
University Hospital, Merseyside, UK, between December
1990 and August 1991 were recruited into this study after
giving informed consent. Controls were derived from patients
attending the Breast Clinic, with or without breast symp-
toms, known not to have suffered from any malignant
disease and found not to have any active breast lesions
following clinical and/or mammographic examination. These
control patients were divided into two groups, those with and
without a family history of breast cancer. Volunteers who
had more than one first-degree relative with a malignant
disease were also excluded. Patients and controls were inter-
viewed and their laboratory and hospital records consulted
and updated accordingly.
The age of the patients, parity (with multiple births treated
as single full childbirth) and menopausal status were
recorded. Premenopausal women were those still menstruat-
ing or, if they were hysterectomised without oophorectomy,
aged 45 years or less. Post-menopausal status was entered
when women had ceased menstruating regularly from natural
causes or had undergone bilateral oophorectomy or ovarian
irradiation without subsequent menstruation, or if they were
hysterectomised without bilateral oophorectomy aged 55 or
over. Menopausal status was recorded as unknown if the
patient had a hysterectomy without oophorectomy and was
aged between 45 and 55 years of age.
A history of malignant disease excluding skin neoplasia
suffered by the patient was recorded, and a detailed family
history of breast cancer and any other cancers of first-degree
relatives (siblings, offspring, parents, aunts, uncles, grand-
parents) and second-degree relatives such as cousins was also
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recorded. Menarche, age of first childbirth and history of
lactation were not considered.
Mammographic records when tumours were impalpable
were recorded as mass; microcalcification or stromal (paren-
chymal) deformity; or a combination of these. Pathological
results were recorded according to the original report given
for clinical management, except for those in which tumour
differentiation was assessed, which were subjected to a fur-
ther review by the study pathologist.
Serum
Blood was obtained and centrifuged within 2 h of collection.
The serum was divided into aliquots of 1.5 ml and stored in
cryovials at -20°C until required. Only one sample was
taken from the control group. From the breast cancer group
sera were collected as follows:
1. Patients with carcinoma in situ (CIS) and early breast
cancer: at time of diagnosis, 6 weeks after primary
treatment and 6 months after primary treatment.
2. Patients with advanced breast cancer: at time of diag-
nosis, 6-8 weeks after commencing chemotherapy and
6 months after last chemotherapy.
The breast excision specimens were fixed in 10% neutral
buffered formalin for at least 18 h, inspected, measured, pro-
cessed in paraffin wax and 5jim sections stained with
haematoxylin and eosin.
type) and the p53 protein immunoprecipitated at 48 h. This
was purified on an SDS-PAGE gel, which was subsequently
transferred to nitrocellulose filters and exposed to the
patient's serum diluted at 1:50. Detection was based on
further incubation of the filters with '25I-labelled protein A
(Figure 1). Tissue sections from paraffin-embedded material
on the corresponding biopsy were analysed by the avidin-
biotin-immunoperoxidase method using CM1 polyclonal
antibody to p53 protein supplied by D. Lane, University of
Dundee, Scotland, UK, and a biotinylated swine anti-rabbit
secondary antibody (Dako), according to the method of Hsu
et al. (1988). Positive nuclear staining was recorded by com-
parison with Cos-1 cells formalin fixed and embedded in
paraffin. Sections were classified as negative, weakly positive,
positive (equal intensity to the positive control) or strongly
positive. All categories other than negative were taken as
positive for analysis.
The ELISA method was then validated by comparing the
optical density plot of this series with that of the negative
control, and the cut-off point was defined as 2.5 times the
negative control. Two of the 22 patients negative by the
Western technique were found to be positive by the ELISA
method. The dilution titre of the six positive patients gave a
linear curve within the dilution range 1:10 up to 1:5,000, and
for the analysis of the test sera, serum diluted at 1:200 was
used, a 4-fold greater dilution than employed in the
immunoblotting method. Maximum detection of the p53
antibodies by the PAb 122 monoclonal was obtained at a p53
concentration of 3ytg ml-1, 50 tLI of which was applied to
each well.
Methods
The definitive study of the sera from 285 patients and con-
trols was carried out using an ELISA technique, in which
soluble p53 protein with deletion of 132 amino acids from
the N-terminus was produced in the Marie Curie Institute by
the polymerase chain reaction and cloning in the pDS/RSB
bacterial expression plasmid (Gentz et al., 1989). Identity of
the polymerase chain reaction product to wild-type human
p53 was confirmed by sequencing. The fragment of p53 was
expressed in Escherichia coli and, after harvesting by cen-
trifugation and lysis, the protein supernatant was purified on
an Ni-NTA agarose column (Quiagen). Renaturation was by
serial dialysis in 25 mM Tris-HCl buffer, pH 8, with decreas-
ing concentrations of guanidine hydrochloride. After incuba-
tion, unbound p53 was removed by washing and 50 yl from
each serum sample at a standard dilution of 1:200 was then
added to each well in triplicate, after a blocking step with
bovine serum albumin. Standard controls comprised a set of
wells with the monoclonal antibody to p53 PAb 122 (Boeh-
ringer Mannheim) and a set of pooled positive sera and
pooled negative sera from an initial series of samples assayed
by immunoblotting. Peroxidase-conjugated rabbit anti-
human secondary antibody to IgG was then added to each
well, and the optical density was determined at 490 nm after
reaction with OPD (Dako). As additional proof of the
specificity of the method for antibodies to p53, preincubation
of the positive control sera with the purified p53 protein
caused a downward shift in the curve of optical density
plotted against serum dilution in the range 1:100 to 1:1,000
for the controls positive by immunoblotting. Twelve sera (six
ELISA positive, six ELISA negative) were tested for anti-
nuclear antibody by indirect immunofluorescence on rat liver
sections and HEP/2 cells, and against double-stranded DNA
by ELISA. These assays were carried out in the Regional
Immunology Laboratory, Royal Liverpool University Hos-
pital, and subject to national quality control criteria. All 12
sera were negative.
In order to identify positive sera with p53 antibodies, sera
from a separate series of 26 patients with breast cancer were
assayed for these antibodies by a Western blotting method,
similar in outline to that employed by Winter et al. (1992),
and four (15.4%) were found to be positive. Full details of
the technique are available from the authors. Monkey Cos-1
cells were transfected with the p53 gene (mutant and wild
Statistical methods
The precision of the ELISA method was tested using linear
regression analysis. The relationship between individual and
grouped clinical and pathological variables was tested by
means of chi-square tests for contingency tables with ordered
categories (Armitage & Berry, 1987). Multiple analyses were
performed by means of multiple linear regression analysis.
All the P-values used were two-sided, and P-values of less
than 5% were judged to be statistically significant.
Results
Serum antibodies to p53 were detected in 26% (48/182) of
the sera of breast cancer patients, compared with 1/76 of the
control patients (P = 0.0001). Of the 99 tumours graded
according to the modified classification of Bloom and Field,
(1971) (Table I), a significant positive correlation was found
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Figure 1 Western immunoblot analysis of a test series of breast
and lung cancer sera. A 50% mixture of mutant (conserved box
5) and wild-type p53 is run on the gel and, after incubation with
test serum and development with "3'iMlabelled protein A, a
positive result is shown by a band at a molecular weight of
53 kDa. The positive control (lane 1) employs a mouse mono-
clonal antibody to human p53 instead of test serum.p53 AUTOANTIBODIES IN BREAST CANCER 1117
between seropositivity and poor tumour differentiation
(P<0.0012).
At least two serum samples were obtained at least 6 weeks
apart in 22 of the 182 patients. In eight patients three or
more serum samples were assayed over a period of 6 months
or more. p53 antibody status did not change with time in
serial serum samples. These findings include the results in the
four patients who were found to have host antibodies to p53
by the immunoblotting method on the first sample, and who
continued to be seropositive for antibodies by ELISA in their
subsequent serial sera. Even in patients with in situ disease in
whom the tumour had been surgically removed at least 6
months prior to the second sample, there was no significant
change in serum titre. However, two patients who had been
found negative by immunoblotting in the original series of 26
patients were found to be seropositive by ELISA.
Patients with high titres and high optical density
absorbency at the beginning continued to exhibit high levels
in subsequent sera. Similarly, those with lower or moderate
titre levels maintained similar levels over 6 months. The
relationship between p53 autoantibody status and the clinico-
pathological parameters of breast cancer is shown in Table
II. In 40 patients the tumours were smaller than 2 cm, and in
114 patients they were 2 cm or more. In the remainder (28
patients) no tumour measurements were available. No
obvious associations could be made between p53 host anti-
body status and either size of tumour (P = 0.42) or axillary
lymph node metastases (P = 0.435). Sixty-two patients were
free of axillary node metastases and 57 had lymph node
Table I Correlation between p53 host antibody and histological
grade of breast cancer
Grade Negative Positive Total
I 21 1 (6%) 22
II 42 7 (14%) 49
III 36 22 (38%) 58
Not available 20 10 (33%) 30
x2=13.52, P<0.0012. x2= 12.77, P<0.0004.
Table II The relationship between p53 autoantibody and
clinicopathological parameters of breast cancer
Parameter Negative Positive Total
Size oftumour (cm)
<2.0
> 1.9
X2=0.63,P = 0.42
Lymph node metastases
None
1-3
>3
Unknown
32 8 (20%) 40
82 32 (28%) 114
48
20
20
31
14(22%)
6(23%)
11(35%)
9 (22%)
62
26
31
40
XI = 2.18, P = 0.53; X2 fortrend = 1.57, P = 0.21 (0+ 3 metastases)
Distant metastases
Lungand pleural
Liver
Bone
Meningeal
Locally advanced
Total
Stage ofbreast cancer
Stage I
Stage II
Stage III
Stage IV
Not available
3 1
4 0
2 3
1 0
9 4
19 8
17
60
19
12
8
2 (10%)
19(24%)
5 (20%)
7 (36%)
5(31%)
4
4
13
27
19
79
24
19
13
X2= 3.778, P = 0.2864.
x2 for trend = 2.535, P = 0.114.
metastases. All the tumours were characterised and typed,
and 127 patients were classified as having ductal carcinoma
of no specific type, 16 as having lobular carcinoma and 23 as
having ductal carcinoma in situ (DCIS). There was no
association between serological status and histological type.
While eight of the DCIS patients were positive, there was no
effect of the presence or absence of associated extensive
DCIS in the biopsies.
Some of the subsets of metastatic and locally advanced
breast cancer patients (Table II) showed a high prevalence of
seropositivity (3/5 with bone metastases, 1/3 with lung and
4/9 locally advanced disease), but none of the four patients
with liver metastases, of whom two were jaundiced, were
found to have autoantibodies to p53, and of a total of 27
advanced breast cancer patients eight (29.6%) were found to
be seropositive. There was no significant association with
tumour stage. Table III demonstrates that a high Notting-
ham prognostic index was associated with the presence of
serum p53 autoantibodies (P = 0.03). This index provides a
score summating histological grade and extent of tumour
spread (Ellis et al., 1992).
The association of p53 autoantibody with the character-
istics of the breast cancer patients is shown in Table IV. In a
subset of women not subject to mammographic screening
programmes (i.e. less than 50 years of age), 7 of 15 patients
(47%) aged below 40 were found to be seropositive for
autoantibodies to p53 compared with 18% (8/43) of patients
aged between 40 and 49. Thirty per cent (14/46) of sero-
positive women were premenopausal and the majority (41/46)
Table III Nottingham prognostic index (Ellis et al., 1992)
Negative Positive Total
<3.4 41 7 (14%) 48
3.4-5.4 22 11(33%) 33
> 5.4 31 16(34%) 47
Unknown 20 6(23%) 26
x2= 5.655, P =0.059; x2fortrend = 4.633, P = 0.0314.
Table IV The association of p53 autoantibody and the personal
clinical history of breast cancer patients
Negative Positive Total
Age atdiagnosis (years)
<30 1 l
30-39 7 7(50%) 14
40-49 34 8 (18%) 43
50-59 38 17 (30%) 55
60-69 32 9(21%) 43
70-79 13 6(31%) 19
> 79 4 1 (20%) 5
X2 = 6.34, P 0.274;x2 fortrend 0.406, P 0.52
Parity
Nulliparous 26 12 (30%) 38
Parous 75 30 (27%) 105
Unknown 32 7 (11%) 39
x2 = 0.122, P = 0.7272
Menstrual status
Premenopausal 32 14(30%) 46
Post-menopausal 87 32(27%) 121
Unknown 17 2 (10%)
x2= 0.207, P = 0.6489
Previous malignancy
other than breast 2 6(75%) 8
Number offirst-degree relatives with cancer
Breastcancer 30 3 (11%) 33
Two ormorecancers 16 6(37%) 22
x2= 2.00, P = 0.157 (Fisher's exact P = 0.079)1118 B. MUDENDA et al.
Figure 2 Breast cancer section stained with the polyclonal CMI
antibody to human p53 and developed by the avidin-biotin-
immunoperoxidase method. Positive nuclear staining is observed
(x 200).
Table V Correlation between p53 host antibody and p53 staining in
breast tumours
Negative Positive
Seropositive (n = 23) 5 18 (78%)
Seronegative (n = 45) 29 16(35.5%)
x= 9.46, P <0.002.
were symptomatic. Of the premonopausal seropositive
women, 42% (6/14) seropositive patients were found to have
grade 3 tumours.
Figure 2 shows an example of positive nuclear staining for
p53 in a breast carcinoma. When the presence of autoanti-
bodies in the sera by the ELISA technique was compared
with immunocytochemical localisation of p53 protein in 68
corresponding tumours, there was good correlation
(P = 0.002) between seropositivity and the presence of p53 in
tumours (Table V). In the seronegative patients the over-
expression of p53 in the tumour biopsies was found to
correlate positively with a family history (P = 0.009). Six
(75%) out of eight patients who had suffered from another
primary cancer apart from breast cancer (patients with a
second primary breast tumour were not included) were found
to exhibit p53 host antibodies in their serum. Three patients
had both the primary tumours immunohistochemically
stained for p53, and in two of these evidence of p53 over-
expression was found in both.
A family history of two or more relatives with cancers
other than breast cancer also appeared to be significantly
associated with seropositivity for p53 autoantibodies. How-
ever, only 3 out of 33 (9%) breast cancer patients with a
family history of breast cancer were found to have autoan-
tibodies to p53, compared with 42 out of 143 breast cancer
patients without a family history who were seropositive
(P = 0.046). All the three seropositive were patients with only
one relative with breast cancer, and none of the seven breast
cancer patients with two or more relatives with breast cancer
exhibited autoantibodies to p53.
Discussion
This study has demonstrated a higher prevalence (26%) of
serum autoantibodies to p53 protein than previously demon-
strated by immunoblotting techniques which have shown
prevalence rates between 11 and 15% (Crawford et al., 1982,
1984; Caron de Fromentel et al., 1987; Davidoff et al., 1992;
Winter et al., 1992). This high prevalence approaches that of
the value for p53 mutation (c. 30%) in breast cancer. How-
ever, it is likely that mutation is only one mechanism of
inactivation of p53. The most significant observation was the
association with poor histological grade, as has also been
noted in one recent study (Schlichtholz et al., 1992). There
was also a good correlation between seropositive status and a
high Nottingham prognostic index. The presence of p53
autoantibodies has also been shown to be associated with the
subset of p53 mutants which bind tightly to heatshock pro-
tein 70 (Davidoff et al., 1992). Such mutations have strong
transforming properties in vitro, and this would be consistent
with their presence in tumours of poor histological grade.
The relationship to metastatic disease in the present study
was not clear, with a trend in favour of a higher prevalence
in more advanced disease, as was noted by Crawford (1984)
in his original series. However, Schlichtholz et al. (1992)
found no association with metastases, and therefore sug-
gested that the appearance of antibodies was an early event.
In gastric cancer p53 overexpression may be associated with
a high potential for metastasising to the lymph nodes in
other tumour types (Kakeji et al., 1993), and in cervical
cancer overexpression is common in HPV-negative tumours
which have a poor prognosis (Crook et al., 1992).
There is also conflicting evidence on whether the autoanti-
bodies recognise mutant or wild-type p53. De Leo et al.
(1979) showed in experimental systems that the mutant p53
may be immunogenic. However, Davidoff et al. (1992)
showed in breast cancer that p53 autoantibodies recognise a
variety of wild-type and mutant p53 molecules. Schlichtholz
et al. (1992), on the other hand, using fusion proteins from
parts of the p53 molecule, showed that the antibodies were
recognising sections of the protein near the C- and N-termini
of the molecules, and well away from the mutational hotspot
region in the evolutionarily conserved boxes in exons 4-8
(Winter et al., 1992) in patients with non-small-cell lung
cancer, and Lebrecque et al. (1993) in colon and breast
cancer demonstrated that the antibodies recognised both
wild-type and mutant p53 conformational and denaturation-
resistant epitopes.
The p53 protein employed in the present ELISA method
(but not that in the immunoblotting techniques) is lacking
part of the N-terminal peptide, and therefore these studies
may under-represent the true incidence of serum autoanti-
bodies in breast cancer patients.
The lower prevalence of autoantibodies in the patients with
a family history of breast cancer in the present study is of
interest as it may represent loss of tolerance induced by
strong accumulation of wild-type protein in the tumour cell,
a hypothesis advanced by Schlichtholz et al. (1992). Against
this hypothesis is the demonstration of relatively high levels
of protein in the corresponding biopsies of seropositive
patients, which supports the converse hypothesis, that mutant
p53, provisionally of germ-line origin, gives rise to the pro-
duction of antibodies specific to a protein determinant
altered by mutation.
Thor et al. (1992) made the observation that 42% of 76
hereditary breast cancers showed positive tissue staining for
p53, with approximately similar proportions ofpositive stain-
ing in breast and breast/ovarian cancer families. In the pre-
sent series the majority of patients who showed tissue p53
overexpression were also found to be seropositive. There
were also a number of patients who were positive by ELISA
yet negative by immunocytochemistry. This observation was
also made by Crawford et al. (1984), who found that 8 of 14
breast cancer patients positive for autoantibodies had no
detectable p53 in their biopsies. It is suggested that in these
cases the immunogenic stimulus may have occurred at an
earlier stage of tumour development, perhaps when a higher
proportion of tumour cells were in cycle, corresponding to a
period of intense proliferative activity.
These observations suggest that serological analysis pro-
vides an assessment of the functional state of the p53 gene in
breast cancer patients, and may prove to be a useful adjunct
to molecular and histochemical methods of tumour charac-p53 AUTOANTIBODIES IN BREAST CANCER 1119
terisation which have to date concentrated on allele loss, gene
mutation and protein expression. The correlation with poor
histological differentiation suggests an association with
adverse biological features.
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